Press archive



altona Diagnostics has announced a partnership with Velsera to customize and incorporate Velsera’s AI-based software platform into the AltoStar® Workflow. The integrated solution utilizes Velsera’s FastFinder Analysis, with the resulting solution for automated Real-Time PCR infectious disease testing set to be available to users of the AltoStar® Workflow in the second half of 2023.



altona Diagnostics GmbH announced the launch of the RealStar® Zoonotic Orthopoxvirus PCR Kit 1.0*, a real-time RT-PCR based reagent system for the detection of zoonotic (non-variola) Orthopoxvirus species specific DNA – including monkeypox virus DNA of the Central and West African strains.



Since May 2022 cases of monkeypox have been confirmed in at least 12 countries, that are not endemic for monkeypox virus, e.g. in the USA, Canada, UK, Germany, Spain, and Australia. Due to this development, altona Diagnostics has received more and more requests from all over the world for PCR tests to detect this virus.



SARS-CoV-2 PCR testing at Hamburg day care centers using a child-friendly way of sample collection

As part of the pilot project SCoPE (SARS-CoV-2 PCR examination), the feasibility of screening for SARS-CoV-2 using PCR analysis is being tested at two Hamburg day care centers. Day care center children and staff will be screened on a voluntary basis for infections with the SARS-CoV-2 coronavirus. The tests can help to determine the current risk of infection at day care centers and to prevent further infections, e.g. by targeted isolation measures.





Hamburg, April 1st, 2021 altona Diagnostics GmbH, today announced the launch of the AltoStar® HIV RT-PCR Kit 1.5, an in vitro diagnostic test, based on real-time RT-PCR technology, for the detection and quantification of human immunodeficiency virus type 1 (HIV-1) specific RNA (groups M, N and O) in human EDTA plasma.


Designed as a dual target assay, the AltoStar® HIV RT-PCR Kit 1.5 allows amplification of separate regions of the HIV-1 genome to monitor HIV infected patients. The ready-to-use kit consists of master reagents, a No Template Control and Quantification Standards calibrated against the 4th WHO International Standard for HIV-1 RNA.